Last month, Servier, gold sponsor of LabCentral, hosted its Golden Ticket ceremony, awarding one “Golden Ticket” to a promising early-stage life-science company developing transformative solutions in areas of high unmet medical need (you can learn more about the winner here). This edition featured a fireside chat discussion, where Christophe Thurieau, Executive Director Research at Servier, and Miriam Lopes Ramos, Head of Data and AI Products for Research at Servier, offered a deep dive into Servier’s digital transformation and how AI is concretely accelerating our R&D value chain.
Moderated by Irene Blat, the discussion explored how AI is much more than just a trend – it’s fundamentally reshaping our scientific approach. The core of Servier’s AI vision is an ambitious commitment to our 2030 goals, where we aim to leverage data and AI to double our probability of success in drug discovery and reduce the time-to-market by up to three years. To achieve this, Servier is investing significantly in digital tools and AI, combining in-house capabilities with targeted partnerships and acquisitions, while placing strong emphasis on adoption through training and upskilling.
During the conversation, the panelists illustrated that this transformation is already a reality across the pharmaceutical value chain. From the earliest stages of discovery, where in-house tools now synthesize information from dozens of databases in minutes rather than hours, to the final stages of regulatory submission where generative AI is cutting drafting times by 30-40%, technology is acting as a powerful force multiplier. This efficiency is further amplified by a balanced ecosystem of partnerships. Whether it is building digital twins with Aitia to identify new therapeutic target, utilizing Google Cloud’s state-of-the-art technical stack for our data, or collaborating with Iktos and Insilico Medicine to design molecules in previously inaccessible chemical spaces, Servier is integrating the most advanced technologies into its R&D strategy.
Looking toward the future, the discussion touched upon the evolving role of the researcher. The consensus was clear: AI will not replace the scientists, but the scientists who embrace these tools will inevitably lead the industry. By automating repetitive tasks and streamlining data analysis, AI allows R&D teams to refocus their expertise on high-level strategy and complex decision-making. As we continue to seek out partners who offer complementary technologies and share Servier’s patient-centric values, the ultimate key to success remains adoption. For Servier to become a best-in-class digital performer, it is the collective engagement of every employee that will translate these powerful tools into therapeutic breakthroughs.
